RenovoRx Names Industry Veteran Mark Voll As Chief Financial Officer To Drive Commercial Growth Beginning Feb 2026

RenovoRx, Inc., a life sciences company focused on developing targeted oncology therapies and commercializing its FDA-cleared RenovoCath® drug-delivery device, announced that Mark Voll has been appointed Chief Financial Officer, effective February 1, 2026. Mr. Voll brings more than 30 years of financial leadership experience, including extensive work with high-growth public companies. 

Over the course of his career, he has served as Chief Financial Officer for several publicly traded technology organizations, where he played a key role in transitioning companies from early growth stages into fully commercial operations. His background includes leading corporate strategies, managing operational expansion, and supporting companies through periods of significant development and market activity.

In his new role at RenovoRx, Mr. Voll will take on responsibilities that include stockholder communications, financial planning, budgeting, and strategic oversight. His operational expertise will support RenovoRx as it continues the commercial rollout of the RenovoCath drug-delivery device while advancing its Phase III TIGeR-PaC clinical trial, a key component of the company’s oncology program.

Shaun Bagai, Chief Executive Officer of RenovoRx, said that Mr. Voll’s arrival marks an important step in the company’s evolution. He noted that 2025 represented a major transition year in which RenovoRx shifted from being solely a clinical-stage company to one with commercial operations. According to Mr. Bagai, Mr. Voll’s extensive experience leading financial functions in public and rapidly growing organizations will be essential as the company strengthens its commercial execution and long-term strategy.

Mr. Voll shared his enthusiasm about joining RenovoRx at this stage of its development. He said the company is uniquely positioned with an innovative therapy platform and a clear vision for improving the lives of cancer patients. Having spent his career helping growth-stage companies scale successfully, he expressed excitement about contributing to RenovoRx’s momentum and supporting its future progress. He emphasized that the company has already built a strong foundation and looks forward to working closely with leadership and the broader team.

Throughout his career, Mr. Voll has guided multiple companies through initial public offerings and successful exits. These include Techwell, Inc. (IPO in 2006, later acquired by Intersil in 2010), Montage Technology (IPO in 2013, acquired by PDSTI in 2014), and Aquantia Corporation (IPO in 2017, acquired by Marvell Technology in 2019). His history of supporting companies through major financial milestones adds further depth to RenovoRx’s leadership.

As Chief Financial Officer, Mr. Voll will oversee the company’s finance team, which will continue to include Ronald B. Kocak, who served as principal accounting officer prior to Mr. Voll’s appointment during a transitional period. The team will also include Lilly Huang, recently appointed Executive Director of Finance, who has previously worked with Mr. Voll and brings additional continuity and expertise to the organization.